Molnupiravir is an oral antiviral medication that was originally developed for treating influenza but later gained attention as a potential therapy for COVID-19. It works by introducing errors into the viral RNA during replication, a process known as “lethal mutagenesis.” By forcing the virus to accumulate mutations at a rate it cannot sustain, molnupiravir reduces the ability of SARS-CoV-2 (the virus responsible for COVID-19) to replicate effectively inside human cells. This mechanism is distinct from other antivirals like remdesivir, which inhibit viral RNA polymerase directly rather than driving mutations.
The drug was developed by Merck & Co. in partnership with Ridgeback Biotherapeutics and received emergency use authorization (EUA) from regulatory agencies in several countries during the pandemic. Clinical trials showed that molnupiravir could reduce the risk of hospitalization or death in adults with mild to moderate COVID-19 who were at high risk of developing severe illness, particularly when administered early in the course of infection. However, its effectiveness appeared lower compared to another oral antiviral, Paxlovid (nirmatrelvir/ritonavir), which led many health authorities to place molnupiravir as a secondary option when other treatments were not available or suitable.
While molnupiravir offered an important tool in the early fight against COVID-19, it also raised concerns. Some scientists questioned the long-term implications of a drug that induces viral mutations, including the theoretical risk of generating new variants, though real-world data did not confirm this as a significant problem. Additionally, animal studies suggested potential reproductive toxicity, so it was generally not recommended for use in pregnant individuals. Despite these limitations, molnupiravir represented a significant milestone as one of the first oral antivirals for COVID-19, providing a much-needed outpatient treatment option during critical phases of the pandemic.
Advertisement:
No products found.
I get commissions for purchases made through links on this website. As an Amazon Associate I earn from qualifying purchases.
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization
Molnupiravir
New Anti-viral drug for COVID-19
Can molnupiravir help COVID-19?
https://ummawaheda.com/can-molnupiravir-help-covid-19/
https://articlebiz.com/article/1052006622-how-effective-is-molnupiravir-for-covid-19
https://medicalreleasesonline.info/molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-covid-19/
Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with COVID-19